Efficacy of Crizotinib After Entrectinib Resistance Due to MET Polysomy in ROS1-Rearranged NSCLC: A Case Report

Toshiaki Takakura; Hiroaki Kanemura; Kazuko Sakai; Kazuto Nishio; Kazuhiko Nakagawa; Hidetoshi Hayashi

doi:10.1016/j.jtocrr.2023.100523

Efficacy of Crizotinib After Entrectinib Resistance Due to MET Polysomy in ROS1-Rearranged NSCLC: A Case Report

JTO Clin Res Rep. 2023 May 4;4(6):100523. doi: 10.1016/j.jtocrr.2023.100523. eCollection 2023 Jun.

Authors

Toshiaki Takakura^{1

2}, Hiroaki Kanemura¹, Kazuko Sakai³, Kazuto Nishio³, Kazuhiko Nakagawa¹, Hidetoshi Hayashi¹

Affiliations

¹ Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan.
² Internal Medicine III, Wakayama Medical University, Wakayama, Japan.
³ Department of Genome Biology, Kindai University Faculty of Medicine, Osaka, Japan.

Abstract

Resistance to ROS1 tyrosine kinase inhibitors is inevitable, but it has been unclear whether crizotinib might be effective after the development of entrectinib resistance. We here present a case of ROS1-rearranged NSCLC that responded to crizotinib after tumor progression due to MET polysomy during entrectinib treatment. This case suggests that crizotinib is an effective option for patients with MET polysomy, even after disease progression on entrectinib.

Keywords: Case report; Crizotinib; Entrectinib; MET polysomy; Non–small cell lung cancer; ROS1.

Publication types

Case Reports